Artificial Intelligence for Alzheimer’s Disease: Promise or Challenge?
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Decades of experimental and clinical research have contributed to unraveling many mechanisms in the pathogenesis of Alzheimer’s disease (AD), but the puzzle is still incomplete. Although we can suppose that there is no complete set of puzzle pieces, the recent growth of open data-sharing initiatives collecting lifestyle, clinical, and biological data from AD patients has provided a potentially unlimited amount of information about the disease, far exceeding the human ability to make sense of it. Moreover, integrating Big Data from multi-omics studies provides the potential to explore the pathophysiological mechanisms of the entire biological continuum of AD. In this context, Artificial Intelligence (AI) offers a wide variety of methods to analyze large and complex data in order to improve knowledge in the AD field. In this review, we focus on recent findings and future challenges for AI in AD research. In particular, we discuss the use of Computer-Aided Diagnosis tools for AD diagnosis and the use of AI to potentially support clinical practices for the prediction of individual risk of AD conversion as well as patient stratification in order to finally develop effective and personalized therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 1×
“As AD is multi-factorial, many conditions can influence the individual risk and age of onset, particularly metabolic impairments (diabetes mellitus, hypertension, obesity, and low HDL cholesterol), depression, hearing loss, traumatic brain injury, and alcohol abuse [11].”
BackgroundRetractedLeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Grad-CAM: Visual Explanations from Deep Networks via Gradient-Based Localization
Selvaraju, R. R., Cogswell, M., Das, A., Vedantam, R., Parikh, D., & Batra, D. (2017) · 2017 IEEE International Conference on Computer Vision (ICCV) · doi:10.1109/iccv.2017.74 · Cited by 24,513
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
No free lunch theorems for optimization
Wolpert, D. H., & Macready, W. G. (1997) · IEEE Transactions on Evolutionary Computation · doi:10.1109/4235.585893 · Cited by 14,237
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288 · cited 1×
“In the so-called “Omics era”, several databases of omics data—not limited to or specific for neurodegenerative diseases—have been established, such as the Gene Expression Omnibus (GEO), which collects functional genomics data of array- and sequence-based data regarding many physiological and pathological conditions, i…”
BackgroundSudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“Finally, UK Biobank collects and stores healthcare databases and associated biological specimens for a wide range of health-related outcomes from a large prospective study including over 500,000 participants [39].”
BackgroundNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Rajkomar, A., Dean, J., & Kohane, I. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1814259 · Cited by 4,579
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Grandmaster level in StarCraft II using multi-agent reinforcement learning
Vinyals, O., Babuschkin, I., Czarnecki, W. M., Mathieu, M., Dudzik, A., Chung, J., Choi, D. H., Powell, R., Ewalds, T., Georgiev, P., et al. (2019) · Nature · doi:10.1038/s41586-019-1724-z · Cited by 3,455
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
The practical implementation of artificial intelligence technologies in medicine
He, J., Baxter, S. L., Xu, J., Xu, J., Zhou, X., & Zhang, K. (2019) · Nature Medicine · doi:10.1038/s41591-018-0307-0 · Cited by 2,246 · cited 1×
“Notably, coupling AI with data from wearables enables almost real-time non-invasive diagnostics, potentially preventing drop-out at subject level [30].”
MethodXAI—Explainable artificial intelligence
Gunning, D., Stefik, M., Choi, J., Miller, T., Stumpf, S., & Yang, G.-Z. (2019) · Science Robotics · doi:10.1126/scirobotics.aay7120 · Cited by 2,053
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
The Diagnosis and Management of Mild Cognitive Impairment: A Clinical Review
Langa, K. M., & Levine, D. A. (2014) · JAMA · doi:10.1001/jama.2014.13806 · Cited by 1,337 · cited 1×
“Evaluation of MCI patients is often noisy, due to the fact that cognitive impairment can have different etiology and manifestations, as defined by multiple biological and clinical factors [94,101,102].”
BackgroundJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“However, AD shares many common clinical features with other neurodegenerative dementia, including Lewy body dementia [2], frontotemporal disorders [3], and vascular dementia, making early and differential diagnosis difficult, especially in the first stage of the disease [4,5].”
BackgroundA deep learning framework for neuroscience
Richards, B. A., Lillicrap, T. P., Beaudoin, P., Bengio, Y., Bogacz, R., Christensen, A., Clopath, C., Costa, R. P., de Berker, A., Ganguli, S., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0520-2 · Cited by 1,027 · cited 1×
“In order to make the most of biological experiments and refine their findings, they have to be supported and followed by complex biological modeling, based on mathematical and statistical tools such as Artificial Neural Networks [17].”
MethodGrundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972 · cited 1×
“Yearly, about 15% of MCI patients convert to AD [60,74] and, thus, early and timely identification is crucial, in order to ameliorate the outcome and slow the progression of the disease.”
BackgroundDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · cited 5×
“A possible turning point has emerged with the recent development of ultra-sensitive methods for the detection of brain-derived proteins in blood, making it possible to measure NFL [84], Aβ42, and Aβ40 [85,86], and tau and P-tau in plasma [87,88].”
MethodInfluentialSchneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910
The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set
Beekly, D. L., Ramos, E. M., Lee, W. W., Deitrich, W. D., Jacka, M. E., Wu, J., Hubbard, J. L., Koepsell, T. D., Morris, J. C., & Kukull, W. A. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318142774e · Cited by 907 · cited 1×
“Moreover, the National Alzheimer’s Coordinating Center (NACC) has constructed a large relational database for both exploratory and explanatory AD research, by use of standardized clinical and neuropathological research data [35]; DementiaBank, the component of TalkBank dedicated to data on language in dementia, provid…”
MethodHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 2×
“Amyloid plaques and neurofibrillary tangles are the neuropathological hallmarks of the disease [9,10], which can be evaluated in vivo by neuroimaging investigation and cerebrospinal fluid (CSF) biomarker assessment; namely, considering amyloidβ1-42 (Aβ42), its ratio with amyloid β1-40 (Aβ42/Aβ40), total tau protein (t…”
MethodAutomated machine learning: Review of the state-of-the-art and opportunities for healthcare
Waring, J., Lindvall, C., & Umeton, R. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.101822 · Cited by 834
A survey on deep learning for multimodal data fusion
Gao, J., Li, P., Chen, Z., & Zhang, J. (2020) · Neural Computation · doi:10.1162/neco_a_01273 · Cited by 821 · cited 2×
“In order to overcome this limitation and extract multimodal feature representations, DL architectures can be used, which do not need feature engineering, due to their ability to non-linearly transform input variables [78].”
BackgroundDocosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“The AD pathology is characterized by high complexity and heterogeneity, and many authors have demonstrated the absence of etiological uniformity and diverse treatment suitability for each patient, supporting the need for an accurate individual diagnosis [15,16].”
BackgroundExplainable Deep Learning Models in Medical Image Analysis
Singh, A., Sengupta, S., & Lakshminarayanan, V. (2020) · Journal of Imaging · doi:10.3390/jimaging6060052 · Cited by 718
Artificial intelligence for clinical trial design
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.005 · Cited by 672 · cited 1×
“Participant selection can be optimized by using AI algorithms on genetic and clinical data, thus predicting which subset of the population may be sensitive to new drugs [29].”
MethodMultimodal Neuroimaging Feature Learning for Multiclass Diagnosis of Alzheimer's Disease
Liu, S., Liu, S., Cai, W., Che, H., Pujol, S., Kikinis, R., Feng, D., Fulham, M. J., & ADNI (2015) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2372011 · Cited by 637
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622 · cited 2×
“Recently, AI approaches for AD research have shown promising results, providing precise, effective, and convenient methods for assessing AD diagnoses as well as MCI progression in different settings, thanks to the ability to process very large amounts of clinical, biological, environmental, and lifestyle data [51,110,…”
BackgroundYoung, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., Cash, D. M., Thomas, D. L., Dick, K. M., Cardoso, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05892-0 · Cited by 596
A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18 F-FDG PET of the Brain
Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., Lituiev, D., Copeland, T. P., Aboian, M. S., Mari Aparici, C., et al. (2019) · Radiology · doi:10.1148/radiol.2018180958 · Cited by 577 · cited 1×
“8 months prior to the final diagnosis [50].”
BackgroundThe Natural History of Alzheimer's Disease: Description of Study Cohort and Accuracy of Diagnosis
Becker, J. T. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540180063015 · Cited by 576
Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study
Singh-Manoux, A., Dugravot, A., Fournier, A., Abell, J., Ebmeier, K., Kivimäki, M., & Sabia, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0660 · Cited by 529
Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524 · cited 3×
“The accuracy of plasma biomarkers was compared with corresponding markers in CSF, and with the diagnostic prediction of expert physicians in memory clinics, based on the assessment at baseline of extensive clinical assessments, cognitive testing, and structural brain imaging [88].”
MethodGlobal evolution of research in artificial intelligence in health and medicine: a bibliometric study
Tran, B. X., Vu, G. T., Ha, G. H., Vuong, Q.-H., Ho, M.-T., Vuong, T.-T., La, V.-P., Ho, M.-T., Nghiem, K.-C. P., Nguyen, H. L. T., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030360 · Cited by 472 · cited 1×
“Although promising and rapidly growing, only few of these AI applications have made it to the clinical application stage; nonetheless, AI represents a promising technology to support research and, finally, to develop novel effective therapies [24,31].”
BackgroundPalmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · cited 2×
“Amyloid plaques and neurofibrillary tangles are the neuropathological hallmarks of the disease [9,10], which can be evaluated in vivo by neuroimaging investigation and cerebrospinal fluid (CSF) biomarker assessment; namely, considering amyloidβ1-42 (Aβ42), its ratio with amyloid β1-40 (Aβ42/Aβ40), total tau protein (t…”
MethodPredicting alzheimer’s disease progression using multi-modal deep learning approach
Lee, G., Nho, K., Kang, B., Sohn, K.-A., Kim, D., Initiative, F. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37769-z · Cited by 406
El-Sappagh, S., Alonso, J. M., Islam, S. M. R., Sultan, A. M., & Kwak, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82098-3 · Cited by 363 · cited 1×
“The model achieved a good performance while balancing the accuracy–interpretability trade-off in both AD classification and MCI-to-AD prediction tasks, allowing for actionable decisions that can enhance physician confidence, contributing to the realization of explainable AI (XAI) in healthcare [79].”
BackgroundNeff, R. A., Wang, M., Vatansever, S., Guo, L., Ming, C., Wang, Q., Wang, E., Horgusluoglu-Moloch, E., Song, W.-M., Li, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb5398 · Cited by 324
Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Chang, C.-H., Lin, C.-H., & Lane, H.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052761 · Cited by 257 · cited 2×
“has been shown to be capable of accurately predicting AD, thus achieving state-of-the-art results [52].”
BackgroundMethodStaging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237
Boosting power for clinical trials using classifiers based on multiple biomarkers
Kohannim, O., Hua, X., Hibar, D. P., Lee, S., Chou, Y.-Y., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.022 · Cited by 190
Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining
Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., & Rogaeva, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168812 · Cited by 108
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Kumar, S., Chowdhury, S., & Kumar, S. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0394-8 · Cited by 103
A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease
Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54 · cited 1×
“The AD pathology is characterized by high complexity and heterogeneity, and many authors have demonstrated the absence of etiological uniformity and diverse treatment suitability for each patient, supporting the need for an accurate individual diagnosis [15,16].”
BackgroundAlzheimer’s disease: From basic science to precision medicine approach
Forloni, G. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000079 · Cited by 33
Cited by
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
Explainable artificial intelligence in Alzheimer’s disease classification: a systematic review
Viswan, V., Shaffi, N., Mahmud, M., Subramanian, K., & Hajamohideen, F. (2024) · Cognitive Computation · doi:10.1007/s12559-023-10192-x · Cited by 195
Mirkin, S., & Albensi, B. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1094233 · Cited by 46
Neuroimaging of mouse models of Alzheimer’s disease
Jullienne, A., Trinh, M. V., & Obenaus, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020305 · Cited by 32
Metadata
- Authors
- Fabrizio, C., Termine, A., Caltagirone, C., & Sancesario, G.
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2021-08-14
- Volume
- 11
- Issue
- 8
- Pages
- 1473
- ISSN
- 2075-4418 (ISSN-L)
- OpenAlex
- W3195457683
- Cited by
- 146
- References
- 52
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.